SMFM 27th Annual Meeting 2007
view the interview video: Negative fFN, Who is Still Managed Aggressively and Does it Help?
Abstract
Objective: Elevated levels of fetal fibronectin (fFN) in cervicovaginal secretions beyond 22 weeks gestation are used as a predictor of preterm birth in patients suspected of being in preterm labor. Previous studies have documented a negative predictive value of 97-99.5% of delivering within 7 days of testing. Providers sometimes disregard a negative result and manage the patient aggresively. Our objective was to identify which patients with a negative fFN were being managed aggressively, and if outcomes were improved with such management.
Study Design: Charts were reviewed from 121 patients evaluated in our obstetrical triage unit for "rule-out preterm labor" with negative fFN results over a 2 year period. Patients with singleton pregnancies seen between 22 and 33 6/7 weeks were included. Patient characteristics, management, and outcomes were recorded.
Results: 80 patients were managed expectantly, 41 were managed aggressively (18 were admitted, 29 were given tocolytics, 15 received steroids, 8 received antibiotics). The group managed aggressively were more likely to be dilated 1cm or more (27% vs. 3%, p<.001), or contracting at least every 8 minutes (68% vs. 23%, p<.001). Parity, prior preterm births, age and gestational age at testing were similar between the groups. None of the patients delivered within 7 or 14 days of fFN testing. The rates of preterm birth <37 weeks, <35 weeks and <32 weeks, and fFN to delivery interval were similar between the 2 groups. There was no advantage seen to aggressive management even when analyzing only the "high risk" patients (dilated 2cm, effaced >80%, contracting at least every 4 minutes, or prior preterm birth).
Conclusion: Patients with risk factors for preterm birth are more likely to be aggressively managed in the face of a negative FFN. This aggressive management does not improve outcomes.
Download Dr. Pelaez's poster in PDF format here
0002-9378/$ - see front matter
doi:10.1016/j.ajog.2006.10.853
American Journal of Obstetrics and Gynecology
Volume 195, Issue 6, Supplement S (December 2006)
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Similar delivery times between misoprostol dosages among obese patients reported
May 29th 2024A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.
Read More
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More